JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Smith & Nephew PLC ADR

Closed

30.89 1.68

Overview

Share price change

24h

Current

Min

30.35

Max

30.97

Key metrics

By Trading Economics

Income

35M

331M

Sales

203M

3.2B

P/E

Sector Avg

22.441

67.147

Dividend yield

2.44

Profit margin

10.368

Employees

16,988

EBITDA

133M

856M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+2.96% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.44%

2.36%

Market Stats

By TradingEconomics

Market Cap

-1.5B

14B

Previous open

29.21

Previous close

30.89

Technical Score

By Trading Central

Confidence

Bullish Evidence

Smith & Nephew PLC ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 kwi 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 kwi 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 kwi 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 kwi 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 kwi 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 kwi 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 kwi 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 kwi 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 kwi 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 kwi 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 kwi 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 kwi 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

Smith & Nephew PLC ADR Forecast

Price Target

By TipRanks

2.96% upside

12 Months Forecast

Average 32 USD  2.96%

High 32 USD

Low 32 USD

Based on 1 Wall Street analysts offering 12 month price targets forSmith & Nephew PLC ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

26.64 / 28.37Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat